Conference Program

09:00am EST

Conference Opening & Welcome

C. Ola Landgren, M.D., Ph.D., Conference Chair

09:10am EST

Session 1: Multiple Myeloma

09:10 - 09:25

Treatment of Newly Diagnosed Myeloma, New Directions

Rafael Fonseca

Mayo Clinic, Scottsdale, AZ

09:25 - 09:38

Relapsed/Refractory Myeloma: New Options and Optimal Sequence

Malin Hultcrantz

Memorial Sloan Kettering Cancer Center, NY

09:38 - 09:58

Bispecific Monoclonal Antibodies and CAR T Cells: When and How?

Omar Nadeem

Dana-Farber Cancer Institute, Boston, MA

09:58 - 10:10

Executive Summary

C. Ola Landgren

Sylvester Comprehensive Cancer Center, University of Miami, FL

10:10am EST

Session 2: Debate (LIVE) Will Role of Autologous Stem Cell Transplant for Myeloma Change in the Coming 5 Years?

10:10 - 10:20

Yes

Tom Martin

University of California San Francisco, CA

10:20 - 10:30

No

Noa Biran

John Theurer Cancer Center, Hackensack, NJ

10:30 - 10:40

Q&A

10:40am EST

Break

10:50am EST

Session 3: Debate (LIVE) Will MRD Become Part of Clinical Decision Making in Myeloma in the Coming 5 Years?

10:50 - 11:00

Yes

Luciano Costa

University of Alabama at Birmingham, AL

11:00 - 11:10

No

Suzanne Lentzsch

Columbia University, NY

11:10 - 11:20

Q&A

11:20am EST

Session 4: Leukemia

11:20 - 11:34

Role of MRD in Acute Leukemias: Today and Tomorrow

Martin Tallman

Memorial Sloan Kettering Cancer Center, NY

11:34 - 11:54

MDS Novel Insights on Biology and Intervention

Justin Taylor

Sylvester Comprehensive Cancer Center, University of Miami, FL

11:54 - 12:01

Executive Summary

C. Ola Landgren

Sylvester Comprehensive Cancer Center, University of Miami, FL

12:01pm EST

Session 5: Debate (LIVE) Should Allogeneic Transplant be Offered to an MRD Negative AML Patient?

12:01 - 12:11

Yes

Aaron Viny

Columbia University, NY

12:11 - 12:21

No

Wendy Stock

University of Chicago, IL

12:21 - 12:31

Q&A

12:31pm EST

Break

12:40pm EST

Session 6: Debate (LIVE) Is There a Role for Maintenance Therapy in AML?

12:40 - 12:50

Yes

Gail Roboz

Weill Medical College of Cornell University, NY

12:50 - 1:00

No

Eytan Stein

Memorial Sloan Kettering Cancer Center, NY

1:00 - 1:10

Q&A

01:10pm EST

Break

01:21pm EST

Message from BMS

01:25pm EST

LIVE Satellite Symposium Sponsored by BMS

01:25 - 02:25

Reblozyl Branded MDS Indication. It is been provided to assist you in communicating important prescribing information for REBLOZYL® (luspatercept-aamt).

Christina Hughes

Director, WW Medical Affairs, Hematology Myeloid at Bristol Myers Squibb

Show Summary

02:25pm EST

Session 7: Lymphoma

02:25 - 02:44

Newly Diagnosed Diffuse Large B-Cell Lymphoma: New Directions

John Leonard

Weill Cornell Medicine, NY

02:44 - 02:59

Role of Autologous Stem Cell Transplant and CAR T Cell Therapy in Relapsed Lymphoma

Laurie Sehn

Centre for Lymphoid Cancer, Vancouver, BC, Canada

02:59 - 03:17

Bispecific Monoclonal Antibodies and CAR T Cells: When and How?

Alvaro Alencar

Sylvester Comprehensive Cancer Center, University of Miami, FL

03:17 - 03:30

Executive Summary

C. Ola Landgren

Sylvester Comprehensive Cancer Center, University of Miami, FL

03:30pm EST

Session 8: Debate (LIVE) Is Autologous Stem Cell Transplant still a Standard of Care for Mantle Cell Lymphoma?

03:30 - 03:40

Yes

Anne Beaven

University of North Carolina-Chapel Hill, NC

03:40 - 03:50

No

Bijal Shah

Moffitt Cancer Center, Tampa, FL

03:50 - 04:00

Q&A

04:00pm EST

Break

04:10pm EST

Session 9: Debate (LIVE) Should Every Hodgkin Lymphoma Patient Receive Chemotherapy and an Antibody Drug Conjugate in the First Line?

04:10 - 04:20

Yes

Craig Moskowitz

Sylvester Comprehensive Cancer Center, University of Miami, FL

04:20 - 04:30

No

Ann LaCasce

Dana-Farber Cancer Institute, Boston, MA

04:30 - 04:40

Q&A

04:40pm EST

Session 10

04:40 - 04:57

Novel Treatment Options and Role of MRD in the Management of Chronic Lymphocytic Leukemia

Jennifer Woyach

The Ohio State University in Columbus, OH

04:57 - 05:11

Chemotherapy-free Treatment Options in Low-risk Lymphoma

Matthew Matasar

Memorial Sloan Kettering Cancer Center, NY

05:11 - 05:22

Executive Summary

C. Ola Landgren

Sylvester Comprehensive Cancer Center, University of Miami, FL

05:22pm EST

Session 11: Debate (LIVE) Is There Still a Role for Consolidation Radiation Therapy in Early Stage Hodgkin Lymphoma?

05:22 - 05:32

Yes

Ranjana Advani

Stanford University Medical Center, CA

05:32 - 05:42

No

Anita Kumar

Memorial Sloan Kettering Cancer Center, NY

05:42 - 05:52

Q&A

05:52pm EST

Break

06:05pm EST

Session 12: Debate (LIVE) Should Every T-Lymphoma Patient Receive Chemotherapy and an Antibody Drug Conjugate in the First Line?

06:05 - 06:15

Yes

Neha Metha Shah

Washington University, Saint Louis, MO

06:15 - 06:25

No

Matthew Lunning

University of Nebraska Medical Center, Omaha, NE

06:25 - 06:35

Q&A

06:35pm EST

Break

06:47pm EST

Message from Adaptive Biotechnologies

06:50pm EST

LIVE Satellite Symposium Sponsored by Adaptive Biotechnologies

06:50 - 07:30

MRD Assessment in the Management of Patients with Lymphoid Malignancies

Allison Jacob

Medical Director, Medical Affairs, Adaptive Biotechnologies

07:30pm EST

End of Conference

C. Ola Landgren, M.D., Ph.D., Conference Chair